174 related articles for article (PubMed ID: 37945630)
1. Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer.
Huang KC; Ke TW; Chen JY; Hong WZ; Chiang SF; Lai CY; Chen TW; Yang PC; Chen LC; Liang JA; Chen WT; Chao KSC
Sci Rep; 2023 Nov; 13(1):19440. PubMed ID: 37945630
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation.
Lin YS; Chiang SF; Chen CY; Hong WZ; Chen TW; Chen WT; Ke TW; Yang PC; Liang JA; Shiau AC; Chao KSC; Huang KC
Cancer Immunol Immunother; 2023 Jul; 72(7):2283-2297. PubMed ID: 36881132
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
4. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.
Yamazaki T; Hannani D; Poirier-Colame V; Ladoire S; Locher C; Sistigu A; Prada N; Adjemian S; Catani JP; Freudenberg M; Galanos C; André F; Kroemer G; Zitvogel L
Cell Death Differ; 2014 Jan; 21(1):69-78. PubMed ID: 23811849
[TBL] [Abstract][Full Text] [Related]
5. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
6. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
Gou HF; Huang J; Shi HS; Chen XC; Wang YS
PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer.
Gou HF; Zhou L; Huang J; Chen XC
Mol Med Rep; 2018 Aug; 18(2):2335-2341. PubMed ID: 29956798
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.
Peng RQ; Wu XJ; Ding Y; Li CY; Yu XJ; Zhang X; Pan ZZ; Wan DS; Zheng LM; Zeng YX; Zhang XS
BMC Cancer; 2010 Sep; 10():496. PubMed ID: 20846416
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
10. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells.
Jafari S; Lavasanifar A; Hejazi MS; Maleki-Dizaji N; Mesgari M; Molavi O
Daru; 2020 Jun; 28(1):159-169. PubMed ID: 31942696
[TBL] [Abstract][Full Text] [Related]
11. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.
Cross-Knorr S; Lu S; Perez K; Guevara S; Brilliant K; Pisano C; Quesenberry PJ; Resnick MB; Chatterjee D
BMC Cancer; 2013 Oct; 13():463. PubMed ID: 24098947
[TBL] [Abstract][Full Text] [Related]
12. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
Fang H; Ang B; Xu X; Huang X; Wu Y; Sun Y; Wang W; Li N; Cao X; Wan T
Cell Mol Immunol; 2014 Mar; 11(2):150-9. PubMed ID: 24362470
[TBL] [Abstract][Full Text] [Related]
13. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
Zaanan A; Taieb J
Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions.
Schuring RP; Hamann L; Faber WR; Pahan D; Richardus JH; Schumann RR; Oskam L
J Infect Dis; 2009 Jun; 199(12):1816-9. PubMed ID: 19456232
[TBL] [Abstract][Full Text] [Related]
15. The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents.
Zhang CC; Gdynia G; Ehemann V; Roth W
Int J Oncol; 2015 Feb; 46(2):667-76. PubMed ID: 25434832
[TBL] [Abstract][Full Text] [Related]
16. Choosing the Appropriate Individualized Adjuvant Chemotherapy in Stage III Colon Cancer Patients Under and Over 70 Years.
Taha HF; Harb OA; Gertallah LM; Abdelaziz LA
J Gastrointest Cancer; 2022 Sep; 53(3):581-591. PubMed ID: 34282542
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
[No Abstract] [Full Text] [Related]
18. Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression.
Huang WS; Lin CT; Chen CN; Chang SF; Chang HI; Lee KC
J Cell Biochem; 2018 Aug; 119(8):6943-6952. PubMed ID: 29737584
[TBL] [Abstract][Full Text] [Related]
19. Relationship of dendritic cell density, HMGB1 expression, and tumor-infiltrating lymphocytes in non-small cell lung carcinomas.
Aguilar-Cazares D; Meneses-Flores M; Prado-Garcia H; Islas-Vazquez L; Rojo-Leon V; Romero-Garcia S; Rivera-Rosales RM; Lopez-Gonzalez JS
Appl Immunohistochem Mol Morphol; 2014; 22(2):105-13. PubMed ID: 24752173
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
